Vertex Pharmaceuticals' lumacaftor/ivacaftor for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read MoreMAY 12 PADAC BS
Vertex Pharmaceuticals' lumacaftor/ivacaftor for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read MoreMAY 12 PADAC
Vertex Pharmaceuticals' lumacaftor/ivacaftor for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read MoreOCT 21 PADAC
Vertex's Kalydeco (ivacaftor) for cystic fibrosis with the R117H mutation
Read MoreOCT 21 PADAC
Vertex's Kalydeco (ivacaftor) for cystic fibrosis with the R117H mutation
Read MoreOCT 21 PADAC
Kalydeco (ivacaftor) oral tablets, by Vertex Pharmaceuticals, for cystic fibrosis in patients with an R117H mutation
Read MoreOCT 21 PADAC
Kalydeco (ivacaftor) oral tablets, by Vertex Pharmaceuticals, for cystic fibrosis in patients with an R117H mutation
Read More